If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epithalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Khavinson cartilage / connective-tissue bioregulator
Supply and ordering
Ask sales about Cartalax availability, order quantities, packaging, and batch documentation. Include other catalog items in the same inquiry if you are planning a combined or recurring order.
Overview
Cartalax is a Khavinson-class short-peptide bioregulator positioned within the Khavinson framework as the cartilage and connective-tissue regulatory peptide, targeting chondrocyte gene-expression programs and connective-tissue maintenance pathways under the shared hypothesis that short tissue-specific peptides act as endogenous bioregulators in their target tissues. The cartilage-tissue positioning makes Cartalax relevant to research workflows studying joint health, chondrocyte biology, and connective-tissue regeneration models. PeptideXpo supplies Cartalax as a lyophilized 20 mg vial at ≥99.0% HPLC purity. As with the rest of the Khavinson class, CAS is not consistently registered across suppliers and identity is established via sequence verification on the batch COA. The exact sequence varies by supplier source within the Khavinson framework; buyers should treat Cartalax as a class designation and confirm the sequence matches their reference protocol via COA at batch receipt.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Khavinson bioregulator; CAS commonly not registered. Confirm sequence and identity per batch COA.
Selected literature
Frequently asked questions
Cartalax is positioned within the Khavinson framework as a chondrocyte and connective-tissue regulatory peptide, hypothesized to support cartilage maintenance and joint-tissue gene-expression programs. Published Khavinson-school research on Cartalax focuses on animal models of joint inflammation, age-related cartilage degeneration, and tissue-repair after injury, with the mechanism hypothesis centered on bioregulatory effects on chondrocyte cell-cycle and matrix-protein expression. As with the rest of the Khavinson class, the Western peer-reviewed evidence base is limited, and buyers should reference the original Russian-language publications for protocol design rather than treating Cartalax as a clinically-validated cartilage therapeutic.
Cartalax and BPC-157 occupy different layers of the joint-tissue research landscape. BPC-157 is a Western-developed 15-amino-acid peptide with a substantial published mechanism-of-action literature in Western peer-reviewed journals, and is on the FDA PCAC agenda for 503A bulks-list consideration, it has more regulatory pedigree and broader independent confirmation of its tendon-ligament and connective-tissue effects. Cartalax is a Khavinson-class short peptide with research evidence concentrated in Russian-language sources and limited Western independent replication. For research workflows that need to align with Western clinical or regulatory frameworks, BPC-157 is the more appropriate choice; for buyers specifically studying the Khavinson bioregulator framework or replicating Russian-school protocols, Cartalax is appropriate. The two are not chemically equivalent or pharmacologically interchangeable.
The standard 20 mg lyophilized fill supports 20-100 single-dose research preparations depending on the dose-per-aliquot target. For typical Khavinson-class research protocols using 200-500 μg per administration, the 20 mg vial supports 40-100 doses. Reconstitution should use isotonic saline or appropriate Khavinson-protocol vehicle at near-neutral pH; the reconstituted solution should be aliquoted into single-use volumes (typically 50-200 μL) and held at -20 °C. Freeze-thaw cycling is the dominant in-lab degradation pathway for short peptides, operational guidance is to thaw an aliquot once for the experiment and discard rather than refreezing. The lyophilized 20 mg vial itself follows the standard 24-month re-test window at -20 °C.
Related peptides
4-mer
Khavinson bioregulator tetrapeptide (Ala-Glu-Asp-Leu, AEDL)
4-mer
Khavinson cortical bioregulator tetrapeptide (Ala-Glu-Asp-Pro, AEDP)
